Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Estimating incidence and prevalence of polycythemia vera and associated eligibility for cytoreductive therapies in major US health plans

View Full Paper
Ask AI
Bookmark
Share

Authors

NHNoemi HummelALAlekhya Lavu

Discussion

Loading...

Member takes

Overview

Analysis estimates the incidence and prevalence of polycythemia vera patients eligible for cytoreductive therapies, indicating variability across commercial health plans.

Key Points

  • An average of 50.94 prevalent polycythemia vera patients per 100,000 individuals were identified.
  • Nine sources provided epidemiological estimates for polycythemia vera and related risk classifications.
  • Membership data from eight major health plans contributed to the estimates of therapeutic eligibility.
  • The study highlights significant variability in estimates across US health plans, potentially impacting treatment access.

Cite This Study

Hummel et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc32https://doi.org/10.1182/blood-2025-8202
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Burden of illness and hematocrit control among patients with high- and low-risk polycythemia vera receiving current standard of care treatment in the United States2025
  2. 2Estimating incident and prevalent essential thrombocythemia patients eligible for cytoreductive therapies in the US and Canada2025
  3. 3Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network2025
  4. 4Burden of thromboembolism, disease progression, and phlebotomy among polycythemia vera patients in the United States: a systematic literature review2026
  5. 5Patient and clinician perspectives on the diagnosis and management of polycythemia vera: Results from concurrent surveys2025